An observational study in Pulmonary Hypertension and Hypertension, Pulmonary Arterial, sponsored by Pulnovo Medical (Wuxi) Co., Ltd.. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Pulnovo Medical (Wuxi) Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 13th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2025, is one of 20 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 72nd registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:
Chinese Pulmonary Vascular Disease Research Group · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Qianfoshan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 27 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 148 across the 56 interventional studies, 495 across the 20 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 76 have an industry lead sponsor. The 10 most frequent:
Pulnovo Medical (Wuxi) Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Pulnovo Medical (Wuxi) Co., Ltd. has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Arterial Hypertension with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT06554301China National Center for Cardiovascular DiseasesA Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Real-World Study of PADN for the Treatment of PAH
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's planned enrollment of 200 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →Pulnovo Medical (Wuxi) Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients diagnosed with pulmonary arterial hypertension (PAH) who have undergone PADN procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None specified.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
Clinical worsening
Clinical worsening events defined as any of the following during the study period: 1. PAH-related rehospitalization. 2. Addition of PAH-targeted therapies (increased types/dose of PAH-targeted drugs or diuretics). 3. ≥10% or ≥30-meter reduction in 6-Minute Walk Distance (6MWD) from baseline. 4. Atrial septostomy. 5. Need for lung transplantation. 6. Cardiovascular death.
Time frame: 1 year
WHO Functional Class changes from baseline
Time frame: 6 months, 1, 2, 3, and 5 years
NT-proBNP/BNP levels from baseline
Time frame: 6 months, 1, 2, 3, and 5 years
6MWD changes from baseline
Time frame: 6 months, 1, 2, 3, and 5 years
Incidence of pulmonary infections
Time frame: Through study completion, an average of 5 years
All-cause death
Time frame: Through study completion, an average of 5 years
Echocardiographic changes from baseline
Right atrial diameter (RAD)
Time frame: 6 months, 1, 2, 3, and 5 years
Echocardiographic changes from baseline
Right ventricular end-diastolic diameter (RVDd)
Time frame: 6 months, 1, 2, 3, and 5 years
Echocardiographic changes from baseline
Tricuspid annular plane systolic excursion (TAPSE)
Time frame: 6 months, 1, 2, 3, and 5 years
Echocardiographic changes from baseline
Left ventricular ejection fraction (LVEF)
Time frame: 6 months, 1, 2, 3, and 5 years
Echocardiographic changes from baseline
Left atrial diameter (LAD)
Time frame: 6 months, 1, 2, 3, and 5 years
Echocardiographic changes from baseline
Left ventricular end-diastolic diameter (LVDd)
Time frame: 6 months, 1, 2, 3, and 5 years
Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.
Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 45 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Pulnovo Medical (Wuxi) Co., Ltd.